Abstract: An amphoteric liposome composed of a mixture of lipids, said mixture comprising a cationic amphiphile, an anionic amphiphile and optionally one or more neutral amphiphiles, at least one of said cationic and anionic amphiphiles being chargeable and the respective amounts of said cationic and anionic amphiphiles being selected such there is a stoichiometric excess of positively charged cationic amphiphile at a first lower pH, a stoichiometric excess of negatively charged anionic amphiphile at a second higher pH and said mixture has an isoelectric point intermediate said first and second pHs; characterised in that said positively charged cationic and negatively charged anionic amphiphiles are adapted to form a lipid salt with one another at said isoelectric point. Also disclosed are methods of predicting the fusogenicity of an amphoteric liposome at a given pH, formulating an amphoteric liposome and loading an amphoteric liposome with a cargo moiety.

Abstract: The anti-inflammatory and preventive action of antimicrobial substances can surprisingly be enhanced by the use of polylactic acid particles. Corresponding advantageous products are in particular oral and dental care and cleaning products that—based on the weight thereof—comprise 0.001 to 25 wt. % polylactic acid particles and 0.00001 to 5 wt. % of at least one antibacterial compound from the groups consisting of the benzoates and/or the parabens and/or the Cu salts and/or the Ag salts and/or triclosan and/or hexetidine.

Abstract: Oral and dental hygiene and cleaning agents, which contain, relative to the weight thereof, 0.001 to 25 wt % polylactic acid particles and 1200 to 1600 ppm fluoride have a substantially improved degree of fluoride deposition and offer an optimum compromise between applicability and plaque reduction.

Abstract: The invention relates to oral and dental hygiene- and cleaning agents having an improved taste and a “silky sensation” in the mouth, said agents containing, in relation to their weight, between 0.001 and 25 wt. % poly(lactic acid) particles, between 0 and 15 wt. % sorbitol and between 0 and 30 wt. % glycerol, with the proviso that the total quantity of ingredient(s) in groups b) and c) lies between 5 and 40 wt. %.

Abstract: The invention relates to oral and dental hygiene and cleaning agents which contain, in relation to their weight, between 0.001 and 25% by weight polylactic acid particles and between 1 and 30% by weight precipitated silicic acid(s) with a specific surface area according to ISO 5794-1, Appendix D, of ?60 m2/g. said agents exhibit a reduced damaging action in comparison to pure silicate-based compositions. In particular, the sensitivity of the teeth during and after the cleaning process is reduced.

Abstract: The present disclosure relates to systems for implementing a computer-readable storage device comprising instructions, including a behavior recognizer, that, when executed by a system having a processor, cause the processor to perform operations, for providing personalized proactive assistance to a vehicle user. The operations comprise receiving a behavior input data package comprising a sequence of user events using the behavior recognizer, and determining the behavior input data package indicates proactive assistance to be presented to the vehicle user by the system, using a user behavior model and a machine state model of the behavior recognizer. The disclosure also relates to methods for providing personalized proactive assistance to a vehicle user.

Abstract: A filling device of a fluid conducting system of an extracorporeal blood treatment device is disclosed. The filling device includes a spike that is adapted for connection to a single fluid connector of a medical fluid container of the fluid system and a manually operable fluid blocking mechanism that is arranged directly downstream of the spike and is adapted or provided in such a way so as to remain fluidly connected with the spike while the filling device is in operation. The fluid blocking mechanism has at least one fluid outlet connector that is adapted so that a line section or hose of the fluid conducting system, preferably an arterial line section of a blood purification device, can be connected to it in a detachable manner while the filling device is in operation.

Abstract: A recirculation device of an extracorporeal blood treatment device is disclosed with a preferably universal medical fluid container to which an arterial line section of a fluid conducting system of the extracorporeal blood treatment device can be connected as an option. Furthermore, the recirculation device has a 3-way switch, preferably a 3-way valve, which is arranged directly downstream of the universal medical fluid container. A conduit of the 3-way switch is preferably coupled with a spike or a similar connecting device or is formed in one piece together with it.

Abstract: The present invention relates to a nucleic acid coding for a variant of the Epstein Barr nuclear antigen 2 (EBNA2) for use as a biomarker for predicting the risk of developing multiple sclerosis and/or for screening and/or for the diagnosis and/or prognosis of multiple sclerosis, and to an in vitro method for predicting the risk of developing and/or for screening for multiple sclerosis and/or for the diagnosis and/or prognosis of multiple sclerosis in a subject, comprising the detection of the presence of said nucleic acid.

Abstract: The present invention relates to a patient-specific tumor treatment targeting individual expression patterns of tumor antigens, in particular shared tumor antigens, and individual tumor mutations. In one aspect, the present invention relates to a method for preventing or treating cancer in a patient comprising the steps of: (i) inducing a first immune response against one or more tumor antigens in the patient, and (ii) inducing a second immune response against one or more tumor antigens in the patient wherein the second immune response is specific for cancer specific somatic mutations present in cancer cells of the patient.

Abstract: The present invention relates to the use of strobilurine type compounds of formula I and the N-oxides and the salts thereof for combating phytopathogenic fungi containing a mutation in the mitochondrial cytochrome b gene conferring resistance to Qo inhibitors, and to methods for combating such fungi. The invention also relates to novel compounds, processes for preparing these compounds, to compositions comprising at least one such compound, to plant health applications, and to seeds coated with at least one such compound.

Abstract: Container assemblies (100) that transition between a sealing state and a retained venting state are described. The container assemblies each include a body portion (110) having an open end (113), and a lid portion (120) adapted to cover the open end of the body portion to create an enclosed volume, e.g. reservoir, and additionally comprise a venting feature (140). When the fluid pressure within the enclosed volume is less than a threshold pressure, the lid portion is in a sealing state such that the lid portion and the body portion cooperate to maintain a substantially fluid-tight seal against fluid leaving the enclosed volume. When the fluid pressure is greater than or equal to the threshold pressure, the lid portion is in a retained venting state such that the excess fluid pressure from the enclosed volume vents through the venting feature while retaining the lid portion on the body portion.

Abstract: A process for cooling a hydrocarbon-rich fraction, in particular natural gas, against a refrigerant circuit. In this process, the compressed refrigerant is divided into three refrigerant substreams. Whereas the first substream is work-producingly expanded in a warm expander and the second substream is work-producingly expanded in a cold expander, the third substream is work-producingly expanded at the lowest temperature level. The result therefrom is that the operating point of the cold expander is shifted in such a manner that the refrigeration output of the two expanders is situated in a ratio between 40/60 and 60/40.

Abstract: The present invention relates to fermented nutritional compositions comprising non-digestible oligosaccharides for improving the bioavailability of iron and preventing or treating of iron deficiency, in particular for infants and young children or pregnant women.

Abstract: The present invention relates to a system and method for monitoring in real time the nutriment intake (feed and/or water) of farm animals, including but not limited to poultry, turkeys, pigs and cows, based on the measurement and identification of the nutriment uptake sounds and/or the working of the nutriment supply system, while the presence and eating position of the animals is monitored by using real-time image analysis

Abstract: Matrix metalloproteinases (MMPs) compositions, inactive forms of MMPs (e.g. proMMPs), fragments, mutants, variants or combinations thereof. A pharmaceutical composition comprises one or more of the above in a pharmaceutical carrier. A composition comprises at least one of: a matrix metalloproteinase (MMP), an inactive MMP or a proenzyme (proMMP) thereof, wherein the matrix metalloproteinase (MMPs), inactive MMPs or proMMPs thereof, comprise: MMP-1, MMP-2, MMP-3, MMP-7, MMP-8, MMP-9, MMP-10, MMP-11, MMP-12, MMP-13.MMP-14, MMP-15, MMP-16, MMP-17, MMP-18, MMP-19, MMP-20, MMP-21, MMP-23A, MMP-23B, MMP-24, MMP-25, MMP-26, MMP-27, MMP-28, active fragments, mutants, variants or any combinations thereof. The uses include isolation of cells, in particular stem cells, from tissues, dissociation of tissues, proteins and treatment of a variety of conditions.

Abstract: Antibody drug conjugates (ADC's) that bind to CD37 protein and variants thereof are described herein. CD37 exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention in some embodiments provide a therapeutic composition for the treatment of cancer.

Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. The present invention relates to novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumour cells which can be used in vaccine compositions for eliciting anti-tumour immune responses.

Abstract: A mobile communication and localization device cooperating with a plurality of mobile network devices includes a processing unit; a data structure containing a plurality of entries, each entry containing information about a corresponding mobile network device and a corresponding time stamp; a unit for sending data packets at respective transmission instants, each data packet containing position data indicating the position of corresponding mobile network devices; a unit for receiving data packets sent by sender mobile devices belonging to the plurality of mobile network devices; and a unit for determining the relative position of corresponding mobile network devices based on position data contained in the data packets.

Abstract: A hanging droplet plate (1) comprises a predetermined number of droplet compartments (10) each being capable of receiving a droplet of a liquid. The respective droplet compartment (10) comprises a circumferential microfluidic wetting barrier (102) which is arranged to surround a respective cavity (100) and which prevents a droplet from spreading beyond the microfluidic wetting barrier (102). The respective compartment (10) comprises a closed bottom (101) and at least one additional circumferential microfluidic wetting barrier (104), each additional circumferential microfluidic wetting barrier (104) which is arranged to surround a preceding circumferential microfluidic wetting barrier (102). A wettable area (103) is arranged between two adjacently arranged microfluidic wetting barriers (102, 104).